PTC Therapeutics Given Average Recommendation of “Buy” by Analysts (NASDAQ:PTCT)
PTC Therapeutics (NASDAQ:PTCT) has received an average rating of “Buy” from the nine ratings firms that are covering the stock, Analyst Ratings.Net reports. Eight investment analysts have rated the stock with a buy rating, The average 1-year price target among brokers that have covered the stock in the last year is $41.58.
Several analysts have recently commented on the stock. Analysts at Roth Capital raised their price target on shares of PTC Therapeutics from $34.00 to $43.00 in a research note on Monday, August 18th. They now have a “buy” rating on the stock. Separately, analysts at Oppenheimer initiated coverage on shares of PTC Therapeutics in a research note on Thursday, July 31st. They set an “outperform” rating and a $60.00 price target on the stock. Finally, analysts at Bank of America initiated coverage on shares of PTC Therapeutics in a research note on Tuesday, July 22nd. They set a “buy” rating and a $37.00 price target on the stock.
Shares of PTC Therapeutics (NASDAQ:PTCT) opened at 31.66 on Tuesday. PTC Therapeutics has a 52 week low of $13.15 and a 52 week high of $34.65. The stock has a 50-day moving average of $28.61 and a 200-day moving average of $25.55. The company’s market cap is $928.9 million.
PTC Therapeutics (NASDAQ:PTCT) last announced its earnings results on Thursday, August 7th. The company reported ($0.86) EPS for the quarter, missing the Thomson Reuters consensus estimate of ($0.75) by $0.11. The company had revenue of $1.70 million for the quarter, compared to the consensus estimate of $1.71 million. The company’s quarterly revenue was down 75.5% on a year-over-year basis. Analysts expect that PTC Therapeutics will post $-3.49 EPS for the current fiscal year.
PTC Therapeutics, Inc is a biopharmaceutical company focused on the discovery and development of orally administered, small-molecule drugs that target post-transcriptional control processes.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.